Skip to main content

Shashwatee Bagchi, MD

Academic Title:

Assistant Professor

Primary Appointment:



Institute of Human Virology, N157

Phone (Primary):

(410) 706-4606


(410) 706-3243

Education and Training


  • May 1993: University of Pennsylvania, Bachelor of Arts. Dual Majors: Biology and South Asian Regional Studies
  • June 1995:  Rosalind Franklin University of Medicine and Science, The Chicago Medical School, Masters of Science in Applied Physiology
  • June 1999:  Rosalind Franklin University of Medicine and Science, The Chicago Medical School, M.D

Post Graduate Education and Training

  • June 1999- June 2002: New York Presbyterian Hospital/Columbia Presbyterian Medical Center: Internal Medicine Residency
  • July 2002- June 2004:  Brigham and Women’s Hospital and Massachusetts General Hospital: Infectious Disease Fellowship


Dr. Bagchi's academic background is rich in clinical, educational and international experiences. She has been engaged in clinical care and medical education both in the US and overseas. While abroad, Dr. Bagchi submerged herself in delivering care to HIV-infected persons and training and mentoring physicians in HIV management in sub-Saharan Africa at the epicenter of the global HIV/AIDS epidemic. In her administrative role, she directed a large team of Tanzanian physicians and healthcare workers to implement HIV care and treatment programs throughout Tanzania. Dr. Bagchi's research has involved in studies conducted through the Adult AIDS Clinical Trials Group in Boston, USA and Lusaka, Zambia. Her research interests have evolved and focused more recently on cardiovascular outcomes among HIV and chronic hepatitis C infected patients (see selected Publications).

Research/Clinical Keywords

Infectious Disease, Medicine, Prevention, HIV, hepatitis, cardiovascular disease

Highlighted Publications

Bagchi S, Kempf MC, Westfall, AO, Maherya A, Willig J, and Saag MS.  Can Routine Clinical Markers be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resource Limited Settings?  Clin Infect Dis.  January 2007; 44:135-138.

Kiage JN, Heimburger DC, Nyirenda CK, Wellons MF, Bagchi S, Chi BH, Koethe JR, Arnett DK, and Kabagambe EK. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.  Lipids in Health and Disease 2013; 12:50.

Bagchi S, Patel P, Faramand R, Burrowes S, Hossain MB, Kottilil S, Miller M,  Fantry LE, and Redfield R.  Underutilization of Statins for Prevention of Cardiovascular Disease Among Primarily African-American HIV-Infected Patients. J AIDS Clin Res 2015; 6:9.

Hickey A and Bagchi S. Cardiovascular Disease Risk Assessment Tools in HIV-Infected Patients – Are They Adequate? J AIDS Clin Res 2016; 7:6.

Burrowes S, Cahill P, Kottilil S, and Bagchi S. Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients. Future Virol. (2016) 11(7), 509–527.

Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, and Bagchi S. Risk of Cardiovascular Disease due to Chronic Hepatitis C Infection: A Review.  J Clin Transl Hepatol 2017; 5(4):1-20. doi:10.14218/JCTH.2017.00021.

Research Interests

HIV/AIDS, hepatitis, Infectious Disease, cardiovascular disease

Clinical Specialty Details

HIV, hepatitis, Infectious Diseases

Grants and Contracts


09/01/06 - 08/31/07:

UAB CFAR (Heimburger, D.C., PI)
Nutritional Causes of Early ART Mortality in Zambi
Role: Co-investigator

In a cohort of ART-naïve Zambians with HIV/AIDS who are starting ART at CIDRZ-supported sites and who exhibit major risk factors for early ART mortality (i.e., CD4+ count < 50 cells/mL or BMI < 16 kg/m2), we are (1) determining whether refeeding syndrome occurs, estimating its incidence and (2) examining whether persons who develop refeeding syndrome are at higher risk of early ART mortality or near-mortality than persons who do not develop refeeding syndrome.

03/01/03 - 02/14/08:

P30 AI27767 (Michael Saag, PI)
UAB Center for AIDS Research
Role:  Co-investigator of International Core.

The major objectives of the Center for AIDS Research are: (1) To enhance ongoing outstanding research programs by facilitating interdisciplinary interactions, providing critical shared resource facilities, and providing administrative and fiscal management support mechanisms for Center investigators; (2) To stimulate the entry of junior and established faculty into HIV/AIDS research programs. This will be accomplished through mentoring and training of your investigators and by the continuation of a peer-reviewed, competitive Developmental Grant Program that will provide funding for both developmental and pilot grants; and (3) To stimulate recruitment and program development efforts in AIDS-related areas. The Center has identified new program areas and will assist Departments and Divisions in the process of investigator recruitment. These approaches will ensure continued growth and development of AIDS-related research in the CFAR.

7/1/2013- 6/30/2014:

New Investigator Award
University of Maryland School of Medicine, Institute of Human Virology
Role: Principal Investigator

Cardiovascular Health of HIV-Infected Patients

The purpose of this study is to describe the cardiovascular health of HIV-infected individuals served by the Evelyn Jordan Center (EJC), an urban clinic where the patients are majority African Americans, almost half are women, and many are dependent on illegal substances. There were three main objectives: (1) To evaluate the annual rate of change in CVD risk, as assessed by the Framingham risk score (FRS), in HIV-infected patients enrolled in the EJC during June 1, 2008- May 31, 2012, (2) To identify sociodemographic and clinical factors that are associated with the change of the FRS in that time period, and (3) To determine if specific antiretroviral medications were associated with change of FRS in the EJC patient population. From this longitudinal retrospective cohort, we will be able to evaluate the changing cardiovascular risk factors during the four-year time period, establish a research database from the large clinical cohort, and generate hypotheses for future studies. The proposed study of this grant application arose from one of the analyses of these data, and we anticipate many more since the data collection is ongoing.


5RO1HL125060-02 (Sanjay Rajagopalan, PI)
Role: co-investigator

Exercise MRI evaluation of HIV-PAH Longitudinal Determinants (EXHALTED)

The purpose of this grant is to investigate a novel use of MRI technology with a detailed assessment of cardiopulmonary indices to provide information on the prevalence and progression of PAH and progressive impairment in contractile function of the RV that commonly afflicts HIV patients. We will further analyze inflammatory variables that may predict these changes thus allowing early identification of these patients.


01/01/11- present:

Title IX Ryan White Grant Award (Robert Redfield, PI)
Maryland Department of Health and Mental Hygeine
Role: Sub-investigator

The purpose of the service grant award is to provide comprehensive, quality health care services to HIV-infected patients living in the State of Maryland.

06/01/17- 05/31/22:

K23 HL133358-01A1 (Shashwatee Bagchi, PI)
Role: PI

Elucidating Chronic Hepatitis C Infection as a Risk Factor for Coronary Heart Disease in HIV-Infected Patients

The purpose of this grant is to support the scientific career development of the Principal Investigator to achieve independence as a clinical investigator in an academic institution and to contribute to the field of discovery in HIV/AIDS and hepatitis C. The goal of this research project is to establish the extent to which chronic hepatitis C infection increases the burden of coronary heart disease (CHD) in HIV-infected patients, and to elucidate host inflammatory and immune pathways that predict increased CHD burden.

07/01/17- 06/30/19:

5R01HL125059-03 (Robert Weiss, PI)
Role: subrecipient PI

The Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

The purpose of this grant is to evaluate the role of inflammation on the pathogenesis of coronary atherosclerosis in HIV we will test the hypothesis that an anti-inflammatory intervention, low dose colchicine, improves impaired local coronary endothelial function in HIV+ people with no clinical coronary artery disease.